< LEADERBOARD/s/betaine-tmgErgogenics & methyl donors

Betaine (TMG)

Also sold as: Trimethylglycine · Anhydrous betaine · TMG

A methyl donor and osmolyte studied for selected exercise and homocysteine outcomes. Anhydrous and hydrochloride forms have different clinical contexts.

Energy

COMMUNITY_STACK_RATINGlive · n=0

Community

Not enough ratings yet: 0 of 10

Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.

+ Rate your experience (30 sec, anonymous)

NERD_PROTOCOL // EVIDENCE_MATRIXper goal

Research

EnergyLimited · benefit

Energy: Selective strength signals do not establish everyday energy or reliable sprint-power benefit.

REALITY CHECK // A 2024 synthesis of 17 studies (317 participants; 21% women) found selective maximal-strength improvement: SMD 0.47 (95% CI 0.04-0.89), with a lower-body signal and no clear upper-body benefit. Body-composition and anaerobic-power findings are inconsistent. Homocysteine lowering is a marker change, not proof of fewer cardiovascular events. High-dose chronic use can raise total cholesterol.

Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.

Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.

CHECK_YOUR_BOTTLE.EXEruns in your browser · nothing is sent or stored

Check your bottle

Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.

Enter the amount from your label to see the result.

How it was studied

01 // STUDIED_DOSE_RANGE

Study exposure, not a prescription

Exercise trials typically used 2.5 g/day anhydrous betaine for at least 7 days. Homocysteine/liver research used different, often higher exposures around 3-6 g/day. Remethylation-disorder treatment requires specialist care. These are study descriptions rather than personal regimens.

02 // TIMING_&_MATRIX

Chronic exposure, not an acute stimulant

Betaine is an osmolyte and methyl donor in homocysteine remethylation. Plausible mechanisms do not establish muscle growth or cardiovascular prevention. Betaine HCl also adds acid and has a different clinical context.

03 // EVALUATION_WINDOW

At least 7 days; trials extend weeks

Acute biochemical responses and chronic clinical outcomes have different evaluation windows; the outcome notes specify the study context.

04 // SAFETY_&_QUALITY_GATE

Material, medicines and tolerability

Supplement-dose pregnancy/breastfeeding safety is insufficient. Homocystinuria/remethylation disorders require specialist monitoring; severe complications are described with therapeutic exposures. Ulcers/reflux/acid suppression warrant particular caution with HCl. Dyslipidemia requires review before chronic high-dose use. Nausea, diarrhea and fishy odor can occur.

UPPER LIMIT // No formal EFSA/NIH UL is supplied. A synthesis at at least 4 g/day for 6-24 weeks found total cholesterol +0.34 mmol/L (95% CI 0.02-0.65), without significant LDL/HDL/triglyceride differences in that analysis. A health-claim threshold is not a safety ceiling.

NERD'S NOTENerd Protocols · a clinical and sports dietitian based in the EU

Summary

A 2024 synthesis of 17 studies (317 participants; 21% women) found selective maximal-strength improvement: SMD 0.47 (95% CI 0.04-0.89), with a lower-body signal and no clear upper-body benefit. Body-composition and anaerobic-power findings are inconsistent. Homocysteine lowering is a marker change, not proof of fewer cardiovascular events. High-dose chronic use can raise total cholesterol.

Mechanism

Typical studied dose

Upper limit

No formal EFSA/NIH UL is supplied. A synthesis at at least 4 g/day for 6-24 weeks found total cholesterol +0.34 mmol/L (95% CI 0.02-0.65), without significant LDL/HDL/triglyceride differences in that analysis. A health-claim threshold is not a safety ceiling.

POPULAR_STACKScombos with n ≥ 5

Popular stacks with Betaine (TMG)

Not enough stack data yet. A combination with Betaine (TMG) appears here once 5 people rate the same set.

> Rate my stack

Forms and label traps

Forms compared
Form on label	Active content	Studied range / day	Absorption & GI tolerance	Verdict
Anhydrous betaine / trimethylglycine Best for: Matching anhydrous exercise-study exposure.	100% elemental / active	2500–2500 mg	Readily absorbed; standard exercise material. High quantities can cause nausea, diarrhea or fishy odor.	Studied standard [CHECK // MATERIAL_AND_LABEL] Declared anhydrous ingredient is 100% betaine. The typical exercise-study amount was 2.5 g/day. PMID 39514262 PMID 16365055
Betaine hydrochloride (HCl) Best for: Clinician-directed gastric-acid assessment.	75% elemental / active	no comparable trial range	Provides betaine plus acid. May aggravate ulcers or reflux.	Caution [CHECK // MATERIAL_AND_LABEL] Approximately 75% betaine by supplied stoichiometry. Content conversion does not prove TMG exercise equivalence; the trial-comparison band is disabled. PMID 23980865 PMID 38474790
Food-derived betaine (beetroot/spinach/bran) Best for: Dietary intake rather than a numeric trial match.	Unstandardized: active content unknown	no comparable trial range	Bioavailable but variable concentration. Depends on food matrix and tolerance.	Caution [CHECK // MATERIAL_AND_LABEL] No assay is supplied; beetroot powder mass cannot be converted confidently into betaine.

Common label traps

TRAP_01 // TMG and HCl are interchangeable
Different composition and clinical context prevent transferring exercise or gastric-acid claims between forms.
TRAP_02 // Lower homocysteine proves heart protection
Marker reduction does not establish fewer cardiovascular events. High chronic exposures can raise total cholesterol.
TRAP_03 // It is a proven testosterone muscle-builder
The hormone signal comes from one crossover study; performance and body-composition findings are inconsistent.

Other outcomes studied

Outside the five leaderboard goals. Same evidence levels as above.

MAXIMAL STRENGTH Moderate · benefit
SMD 0.47 overall and 0.49 for lower-body strength; no clear upper-body effect. Small heterogeneous samples limit certainty.
PMID 39514262 PMID 28426517 PMID 22080324
POWER AND JUMP Limited · benefit
Jump SMD 0.36 emerged after a low-quality study was excluded; Wingate and bar-throw power were not clearly improved.
PMID 39514262 PMID 37409757 PMID 32516959
BODY COMPOSITION Limited · no benefit
Small RCTs conflict; favorable results in women are not a consistently replicated effect.
PMID 30064450 PMID 22080324 PMID 32516959
HOMOCYSTEINE Moderate · benefit
Dose-dependent lowering is documented; remethylation-disorder treatment is separate from healthy-user prevention.
PMID 16365055 PMID 18326594 PMID 42231716
FATTY LIVER Limited · no benefit
The major placebo-controlled trial had no clear primary-endpoint superiority; pilot signals do not establish treatment.
PMID 19824078 PMID 40758380 PMID 10994156
TESTOSTERONE Limited · benefit
One crossover trial reported a hormone rise, without established replicated clinical hormonal benefit.
PMID 37409757
HCL DIGESTIVE USE Limited · no benefit
Dog pharmacokinetics, a review framework and a case report do not establish human digestive-symptom efficacy.
PMID 23980865 PMID 38474790 PMID 38695854

Reader questions

Is TMG the same as betaine HCl?

No. Anhydrous TMG is used in most exercise trials; HCl contains about 75% betaine plus acid and has different tolerability.

Can it raise cholesterol?

At at least 4 g/day for 6-24 weeks a synthesis found total cholesterol about 0.34 mmol/L higher. This differs from typical 2.5 g/day exercise protocols.

Does homocysteine lowering prove longevity?

No. A biochemical marker effect does not establish longer life or fewer cardiovascular events.

Stack interactions

Caution PPIs and H2 blockers [CAUTION // CONTEXT_MATTERS]
HCl changes gastric acidity. A dog drug-absorption experiment cannot establish clinical magnitude; review pH-sensitive medication with the clinician.
PMID 23980865 PMID 38474790
Caution Creatine and other methyl donors [CAUTION // CONTEXT_MATTERS]
Mechanistic overlap does not prove incremental benefit. Overlapping powders can obscure total intake; no indexed combination trial establishes synergy here.

Red flags: interactions and who should avoid it

Interactions

HCl changes gastric acidity and may conflict with PPIs/H2 blockers or alter pH-sensitive drug absorption; its indexed pharmacokinetic experiment used dogs. A significant glucose-drug interaction is not established. Methyl-donor overlap does not establish useful stack synergy.

Avoid or ask a doctor first if

Sources (PubMed, 16)

Effects of chronic betaine supplementation on exercise performance: Systematic review and meta-analysis.
PMID 39514262 · 2024 · Journal Article; Systematic Review; Meta-Analysis
SMD 0.47 overall and 0.49 for lower-body strength; no clear upper-body effect. Small heterogeneous samples limit certainty.
Effects of Betaine Supplementation on Muscle Strength and Power: A Systematic Review.
PMID 28426517 · 2017 · Journal Article; Systematic Review
SMD 0.47 overall and 0.49 for lower-body strength; no clear upper-body effect. Small heterogeneous samples limit certainty.
The effects of chronic betaine supplementation on exercise performance, skeletal muscle oxygen saturation and associated biochemical parameters in resistance trained men.
PMID 22080324 · 2011 · Journal Article; Randomized Controlled Trial; Research Support; Non-U.S. Gov't
SMD 0.47 overall and 0.49 for lower-body strength; no clear upper-body effect. Small heterogeneous samples limit certainty.
Betaine supplementation improves CrossFit performance and increases testosterone levels, but has no influence on Wingate power: randomized crossover trial.
PMID 37409757 · 2023 · Randomized Controlled Trial; Journal Article
Jump SMD 0.36 emerged after a low-quality study was excluded; Wingate and bar-throw power were not clearly improved.
Betaine Supplementation Does Not Improve Muscle Hypertrophy or Strength Following 6 Weeks of Cross-Fit Training.
PMID 32516959 · 2020 · Journal Article; Randomized Controlled Trial
Jump SMD 0.36 emerged after a low-quality study was excluded; Wingate and bar-throw power were not clearly improved.
The effects of chronic betaine supplementation on body composition and performance in collegiate females: a double-blind, randomized, placebo controlled trial.
PMID 30064450 · 2018 · Journal Article; Randomized Controlled Trial
Small RCTs conflict; favorable results in women are not a consistently replicated effect.
Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans.
PMID 16365055 · 2006 · Journal Article; Randomized Controlled Trial; Research Support; Non-U.S. Gov't
Dose-dependent lowering is documented; remethylation-disorder treatment is separate from healthy-user prevention.
Dietary and supplementary betaine: acute effects on plasma betaine and homocysteine concentrations under standard and postmethionine load conditions in healthy male subjects.
PMID 18326594 · 2008 · Journal Article; Randomized Controlled Trial; Research Support; Non-U.S. Gov't
Dose-dependent lowering is documented; remethylation-disorder treatment is separate from healthy-user prevention.
First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders.
PMID 42231716 · 2026 · Consensus Statement; Journal Article; Practice Guideline; Systematic Review
Dose-dependent lowering is documented; remethylation-disorder treatment is separate from healthy-user prevention.
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial.
PMID 19824078 · 2009 · Journal Article; Multicenter Study; Randomized Controlled Trial
The major placebo-controlled trial had no clear primary-endpoint superiority; pilot signals do not establish treatment.
Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase.
PMID 40758380 · 2026 · Journal Article; Randomized Controlled Trial
The major placebo-controlled trial had no clear primary-endpoint superiority; pilot signals do not establish treatment.
Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study.
PMID 10994156 · 2000 · Clinical Trial; Journal Article; Randomized Controlled Trial
The major placebo-controlled trial had no clear primary-endpoint superiority; pilot signals do not establish treatment.
Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
PMID 23980865 · 2013 · Journal Article; not classified as human evidence in source catalog
Dog pharmacokinetics, a review framework and a case report do not establish human digestive-symptom efficacy.
Creating a Framework for Treating Autoimmune Gastritis-The Case for Replacing Lost Acid.
PMID 38474790 · 2024 · Journal Article; Review; not classified as human evidence in source catalog
Dog pharmacokinetics, a review framework and a case report do not establish human digestive-symptom efficacy.
Use of Betaine HCl with Pepsin in Esophageal Cancer Patient: A Case Report.
PMID 38695854 · 2024 · Case Reports; Journal Article
Dog pharmacokinetics, a review framework and a case report do not establish human digestive-symptom efficacy.
Betaine Supplementation Moderately Increases Total Cholesterol Levels: A Systematic Review and Meta-Analysis.
PMID 31809615 · 2021 · Journal Article; Meta-Analysis; Systematic Review
Context on the specific material, mechanism or safety topic named in the indexed title; no independent claim verification was performed for this translation.

Community comments

No approved comments yet. Comments are held for moderation.

+ Rate this